Recruiting

Observational Study

Sponsor:

University of Manitoba

Code:

NCT04586764

Conditions

ST Elevation Myocardial Infarction (STEMI) Patients

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Non-Invasive Cardiac System

Study Details

Brief summary:

Proposed novel solution for high-risk heart disease Overall in-hospital mortality among ST elevation myocardial infarction (STEMI) patients is 3-4%, but >50% patients experiencing cardiogenic shock (CS) secondary to STEMI die in the hospital. Evidence suggests early diagnosis and treatment of CS results in improved outcomes, albeit, there is no tool to diagnose CS reliably in a timely fashion in STEMI patients through the continuous monitoring. We hypothesize that bioimpedance-derived hemodynamic measures obtained using the Non-Invasive Cardiac System (NICaS) can facilitate early detection of CS, predict outcomes, and revolutionize the STEMI patient management. The objectives of SHOCk-NICaS study in STEMI patients are to: a) identify the CS early, using NICaS derived cardiac index of ≤1.8L/min/m2 or ≤2.2L/min/m2 with the use of vasopressor and/or inotropes, and compare it with the incidence of CS based upon lactate level ≥2mmol/L, and systolic blood pressure <90mmHg; b): determine the impact of primary percutaneous coronary intervention (PPCI), using NICaS derived hemodynamic measures (stroke volume, cardiac index, cardiac power index, etc), by comparing pre- and post-angioplasty; and c) identify outcome-associated hemodynamic markers. A composite score of death during hospital stay, prolonged hospitalization due to heart failure (>72hrs), and use of inotropic or mechanical circulation support is a primary outcome.

Methodology This is a multi-center, double-blind, prospective cohort study enrolling STEMI patients aged ≥18years visiting at 4 cardiac centers (St Boniface, St. Michael's, McGill University Hospital). Using validated NICaS protocol, hemodynamic parameters will be recorded at baseline, during the PPCI procedure, and within 24-hour post PPCI without altering the standard care. Statistical analysis: Baseline data will be reported as mean±SD or median±interquartile range. The outcomes will be assessed using multivariable logistic regression. We will analyze the impact of age, sex, gender, and ethnicity on hemodynamic measures. The targeted 500 patients will ensure a margin of error of 5% at a 95% CI. So far recruited 76 STEMI patients mark the study feasibility.

Significance This novel study in high-risk STEMI patients will provide a promising cost-effective, rapid, and non-invasive tool to identify CS early; a prompt intervention may curtail the high morbidity and mortality. The meticulously designed pragmatic study outcomes may revolutionize STEMI patient management.

Conditions

ST Elevation Myocardial Infarction (STEMI) Patients

Study ID

NCT04586764

Start date

Oct 9, 2019

Status verified date

Oct, 2020

Completion date

Oct 31, 2024

Anticipated

Primary completion date

Oct 31, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients aged ≥18 years, presenting with EKG confirmed diagnosis of STEMI
  • Able to understand, and consent to participate in the study

Exclusion Criteria:

  • Patients unwilling to participate in the study
  • Patients with any life-threatening medical condition with an expected life span of ≤1 year (e.g., metastatic cancer, terminal COPD)

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Interventions

Non-Invasive Cardiac System

Non-Invasive Cardiac System (NICaS, NI Medical, Israel) is a non-invasive hemodynamic monitoring system that records various cardiovascular parameters including stroke volume, cardiac output, cardiac index (CI), total peripheral vascular resistance, body water content, and cardiac power index, a marker of myocardial contractility by employing the principles of the whole body impedance cardiography.

Primary outcome measure

  • Prolonged hospitalization due to heart failure (> 96 hours) [ Time Frame: At 7 days ]
  • Use of inotropic - vasopressor therapy [ Time Frame: At 7 days ]
  • Use of mechanical circulation support [ Time Frame: At 7 days ]
  • Death [ Time Frame: At 7 days ]
  • Death [ Time Frame: At 30 days ]
  • Death [ Time Frame: At 1 year ]

Central Contacts and Locations

Central contacts

Ashish H Shah, MD, MD-Res (UK),MRCP

204-237-2315ashah5@sbgh.mb.ca

Locations

St. Boniface Hospital

Recruiting

Winnipeg, Manitoba, Canada, R2H 2A6

Contacts

More Information

Sponsor

University of Manitoba

Last update posted

Oct 14, 2020

Last verified

Oct, 2020

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Manitoba on 2020-10-14.